Latest Publication:

Randomized, observer-blind, controlled Phase 1 study of the safety and immunogenicity of the Na-GST-1/Alhydrogel hookworm vaccine with or without a CpG ODN adjuvant in hookworm-naïve adults
Research News

The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This was a Phase 1 randomized study to demonstrate the safety with promising results and can be read at the link below: 

Click here to read the full article
vaccine

Latest News

Ebola virus
A new Ebola outbreak is confirmed in a remote Congo province, with 65 deaths recorded
Health officials have confirmed a new Ebola outbreak in the Democratic Republic of Congo’s Ituri province, where at least 65 people have died and 246 suspected cases have been identified. Authorities are especially concerned because the outbreak may involve a non-Zaire strain of the virus, meaning…
GW's David Diemert interviews for Beacon Magazine
GW VRU tests Pfizer's new vaccine for C. diff
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
Picture of small pox with the outer and inner core
Results show safety and immunogenicity of fractional doses of the MVA-BN mpox vaccine
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.